Survival Analysis Of The Influence Of HER2 Membrane Staining Ratio On Patients With Advanced Breast Cancer

Objective: For patients with HER2-positive advanced breast cancer receiving first-line treatment with trastuzumab,the relationship between HER2 membrane staining ratio and clinical pathology,characteristics of first recurrence and metastasis,and the influence of HER2 membrane staining ratio on prognosis and survival were discussed.Method: Forty patients with HER2-positive advanced breast cancer who received trastuzumab first-line targeted therapy from January 1,2010 to December 31,2015 at the Breast Center of the Fourth Hospital of Hebei Medical University were selected and followed up.At the same time,HER2 immunohistochemical slide was collected and the staining ratio of HER2 membrane was re-interpreted.Using 75% as the cut-off value of membrane staining ratio,all patients were divided into two groups: the group with membrane staining ratio ≥75% and the group with membrane staining ratio < 75%.The clinical pathology,the characteristics of first recurrence and metastasis were compared between the two groups,and the prognosis was analyzed.Results: There was no significant difference in clinicopathological features and first recurrence and metastasis between patients with HER2 membrane staining ratio ≥ 75% and patients with HER2 membrane staining ratio < 75%,P > 0.05.The median progression-free survival time was 16 months in patients with HER2 membrane staining ratio ≥ 75% and 21.5 months in patients with < 75%,P > 0.05,there was no significant difference between the two groups.The median survival time after metastasis was 31.5 months in patients with HER2 membrane staining ratio ≥75% and 46.5 months in patients with < 75%,P > 0.05,there was no significant difference between the two groups.At the end of follow-up,the survival rate of patients with HER2 membrane staining ratio ≥75% was 33.3%,and that of patients with < 75% was 70%,P < 0.05,the difference was statistically significant.Conclusion: For patients with HER2-positive advanced breast cancer receiving first-line treatment with trastuzumab,the proportion of HER2 membrane staining has nothing to do with their clinicopathological features,first recurrence and metastasis characteristics,which may affect their survival rate,but this result should be carefully considered.